PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection

Recruiting

• Conditions: Sepsis; Antibiotic Reaction

• Registration Number: NCT04961580
• Lead Sponsor: Children's Hospital of Fudan University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-7-5
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Inclusion Criteria:<br><br> - Children who are admitted in the pediatric intensive care unit receiving ceftazidime<br> avitbatan sodium<br><br>Exclusion Criteria:<br><br> - No Informed Consent signed<br><br> - Participate in other clinical trials

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) Pharmacokinetic Parameter

Secondary Outcome Measures

Name	Time	Method
Terminal Phase Elimination Half-life (T1/2) Pharmacokinetic Parameter;AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Pharmacokinetic Parameter;AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Pharmacokinetic Parameter;Cmax: Maximum Observed Plasma Concentration Pharmacokinetic Parameter